Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesBEIGF 77 Days Payable is 233.67 as of Jun. 2026, which is 57% below its 10-year median of 547.10. GuruFocus rates BEIGF with a GF Score™ of 77/100 and a GF Value™ of $23.21. The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, BeOne Medicines ranks better than 65.77% on this metric.
The historical rank and industry rank for BeOne Medicines's Days Payable or its related term are showing as below:
BEIGF'
s Days Payable Range Over the Past 10 Years
Min: 221.21 Med: 547.1 Max: 2998.96
Current: 227.08
During the past 13 years, BeOne Medicines's highest Days Payable was 2998.96. The lowest was 221.21. And the median was 547.10.
BEIGF's Days Payable is ranked better than 65.77% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs BEIGF: 227.08
BeOne Medicines's Days Payable
increased
from Jun. 2025 (201.03) to Jun. 2026 (233.67).
It may suggest that BeOne Medicinesdelayed paying its suppliers.
The historical data trend for BeOne Medicines's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BEIGF vs ALNY, RVMD, RPRX: Days Payable Comparison
For the Biotechnology subindustry, BeOne Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BeOne Medicines's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (BEIGF) has a Days Payable of 233.67 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BeOne Medicines and its competitors. This is 57% below median its historical median of 547.10. Over the past decade, BeOne Medicines' Days Payable has ranged from 221.21 to 2,998.96. According to the industry distribution chart, BeOne Medicines ranks #241 out of 704 companies in the Biotechnology industry, placing it in the top 34.2%.
Is BeOne Medicines' Days Payable too high?
BeOne Medicines' current Days Payable of 233.67 is 57% below median its 10-year median of 547.10. Over the past 10 years, this metric has ranged from a low of 221.21 to a high of 2,998.96. The Biotechnology industry median Days Payable is 112.72. BeOne Medicines' value of 233.67 is 107.3% above this industry median. Based on the distribution chart, BeOne Medicines ranks #241 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Days Payable compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #241 out of 704 companies for Days Payable. This puts BeOne Medicines in the upper half of its industry. The industry median Days Payable is 112.72. BeOne Medicines' value of 233.67 is 107.3% above this benchmark. Historically, BeOne Medicines' own Days Payable has ranged from 221.21 to 2,998.96 over the past decade. While the company's 10-year median is 547.10 vs. the industry median of 112.72, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Days Payable of 233.67 is 107.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Days Payable is 233.67, which is 57% below median its own 10-year median of 547.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (BEIGF) has a current Days Payable of 233.67. The stock's GF Value™ is $23.21, compared to a current price of $21.95 — trading 5.4% below its estimated fair value. The current Days Payable is 233.67, which is 57% below median its 10-year median of 547.10 and 107.3% above the Biotechnology industry median of 112.72. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current Days Payable is 233.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (BEIGF) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $21.95 is trading 5.4% below its estimated GF Value™ of $23.21.
Key valuation signals for BEIGF:
Days Payable: 233.67 (57% below median its 10-year median of 547.10)
GF Value™: $23.21 vs. price of $21.95 (5.4% below fair value)
Industry Position: 107.3% above the Biotechnology median (#241 of 704)
No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for BEIGF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEIGF has been successfully added to your 
